HCA HEALTHCARE INC

Explore how HCA Healthcare’s massive photodisinfection trial could slash surgical site infections, cut costs, and reshape the infection‑control market.

Explore how HCA Healthcare’s nasal photodisinfection trial shows 25% SSI reduction, 85% S. aureus clearance, and AI‑powered clinical tools are reshaping surgery outcomes and efficiency.

Discover how HCA Healthcare’s decade‑long stock outperformed the market—uncover the drivers, risks, and future prospects for long‑term investors.

TD Cowen cuts HCA Healthcare’s target price, citing tighter margins, slower revenue growth, and a competitive, regulated market—yet remains bullish on its long‑term prospects.

Discover why HCA Healthcare’s modest weight in Antipodes Global Value Active ETF signals strong value, resilience and growth potential for diversified investors.

HCA Healthcare’s DCF shows a 12‑15% upside, driven by its diverse hospital portfolio, outpatient expansion, and telehealth investments—yet market sentiment and macro‑economic shifts could affect short‑term gains.

HCA Healthcare boosts cash flow and profits by deploying Commure AI revenue‑cycle tech and launching high‑margin brain PET imaging, cutting denials, speeding collections, and adding $12 M+ annually.

HCA Healthcare boosts cash flow by 28% and cuts denial rates 15% after adopting Commure’s AI‑powered revenue‑cycle platform, setting a new standard for health‑system billing efficiency.

Discover how HCA Healthcare’s strategic ASA partnership and WHASC engagement boost stroke care reputation, attract patients, and unlock AI‑driven growth opportunities.

HCA Healthcare’s share slump reflects sector headwinds and earnings gaps—examining margin dips, debt rise, and tech adoption for a clearer path to resilience.